Investor Relations

Corporate Profile

Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest SEC Filings

Form Filing date Description
SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

S-8

Securities offered to employees pursuant to employee benefit plans

S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

Scroll to Top